Analyst Scoreboard 6 Ratings For Clene - Clene - Benzinga
| CLNN Stock | USD 4.15 0.27 6.96% |
About 54% of Clene's investor base is interested to short. The analysis of the overall investor sentiment regarding Clene Inc suggests that many traders are impartial. Clene's investing sentiment overview a quick insight into current market opportunities from investing in Clene Inc. Many technical investors use Clene Inc stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Clene |
Analyst Scoreboard 6 Ratings For Clene - Clene Benzinga
Read at news.google.com
 |
Clene Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Clene can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Clene Fundamental Analysis
We analyze Clene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Clene is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Clene Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Clene stock to make a market-neutral strategy. Peer analysis of Clene could also be used in its relative valuation, which is a method of valuing Clene by comparing valuation metrics with similar companies.
Peers
Clene Related Equities
| IPSC | Century Therapeutics | 5.52 | ||||
| CSBR | Champions Oncology | 4.87 | ||||
| MNOV | MediciNova | 2.99 | ||||
| FHTX | Foghorn Therapeutics | 2.57 | ||||
| IKNA | Ikena Oncology | 2.37 | ||||
| HOWL | Werewolf Therapeutics | 1.52 | ||||
| KZR | Kezar Life | 0.95 | ||||
| IMNM | Immunome | 0.59 | ||||
| NUVB | Nuvation Bio | 0.35 | ||||
| MOLN | Molecular Partners | 0.17 | ||||
| ELYM | Eliem Therapeutics | 1.30 | ||||
| NXTC | NextCure | 2.50 | ||||
| MLYS | Mineralys Therapeutics, | 2.59 | ||||
| SNSE | Sensei Biotherapeutics | 3.57 | ||||
| NKTX | Nkarta | 4.01 |
Check out Clene Hype Analysis, Clene Correlation and Clene Performance. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clene. If investors know Clene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.614 | Earnings Share (5.29) | Revenue Per Share 0.069 | Quarterly Revenue Growth (0.66) | Return On Assets (0.42) |
The market value of Clene Inc is measured differently than its book value, which is the value of Clene that is recorded on the company's balance sheet. Investors also form their own opinion of Clene's value that differs from its market value or its book value, called intrinsic value, which is Clene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clene's market value can be influenced by many factors that don't directly affect Clene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.